A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

March 3, 2022

Study Completion Date

March 10, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

Empagliflozin

DRUG

Placebo

Placebo

Trial Locations (24)

100034

Peking University First Hospital, Beijing

100044

Peking University People's Hospital, Beijing

100191

Peking University Third Hospital, Beijing

101200

Beijing Pinggu Hospital, Beijing

110072

Shengjing Hospital of China Medical University, Shenyang

130041

The Second Hospital of Jilin University, Changchun

200051

Tongren hospital, Shanghai Jiaotong University School of Medicine, Shanghai

200062

Centre Hospital of Putuo District, Shanghai, Shanghai

200240

Shanghai Fifth People's Hospital affiliated to Fudan University, Shanghai

210011

The Second Affiliated Hospital of Nanjing Medical University, Hangzhou

215002

Suzhou Municipal Hospital, Suzhou

215006

The First Affiliated Hospital of Soochow University, Suzhou

230001

Anhui Provincial Hospital, Hefei

266005

The affiliated hospital of medicalcollege qingdao university, Qingdao

300070

Tianjin Medical University Chu Hisen-I Memorial Hospital, Tianjin

310015

The Affiliated Hospital of Hangzhou Normal University, Hangzhou

330006

Jiangxi Provincial People's Hospital, Nanchang

The First Affiliated Hospital of Nanchang University, Nanchang

The Second Affiliated Hospital to Nanchang University, Nanchang

400042

The First Hospital, Chongqing Medical University, Chongqing

404000

Chongqing Three Gorges Central Hospital, Chongqing

410013

The third xiangya hospital of Central South University, Changsha

471000

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

510150

Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04233801 - A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin | Biotech Hunter | Biotech Hunter